



## Jagsonpal Pharmaceuticals announces Q2 FY23 results

**EBITDA grew by 53.6% to ₹ 14.9 crores, EBITDA margin at 24.1%**

**PAT grew by 58.6% to ₹ 10.4 crores**

**New Delhi, November 09, 2022: Jagsonpal Pharmaceuticals Limited** (BSE: 507789, NSE: JAGSNPHARM) today announced the financial results for the quarter ended September 30<sup>th</sup>, 2022

A detailed presentation on the performance is included as part of this press release

₹ in lakhs	Q2 FY23	Q2 FY22	Growth
Revenues	6,052.6	5,839.3	3.7%
Operating EBITDA	1,487.9	968.6	53.6%
EBITDA %	24.1%	16.5%	760 bps
PAT	1041.2	656.4	58.6%

Commenting on the Company's performance, Mr. Manish Gupta, Managing Director stated *"We are pleased with the strategic direction and financial outcome during Q2FY23, which is the first quarter since the change in ownership structure at promoter level. With a strong focus on key brands, we have been able to achieve a 420-bps improvement in gross margin as well as 760-bps improvement in EBITDA margin. The EBITDA margin in the quarter stood at 24.1% and is headed in the right direction.*

*The business added Rs. 14 crores of free cash which further strengthens our balance sheet with an investible balance of Rs. 84 Crore at the end of the quarter.*

*All our key brands did well and gained market share with our Dydrogestrone franchise (Divatrone® and ProRetro®) having over 4% market share. The next six months will be focused on strategic engagement to identify accelerated growth opportunities, even as we drive profitability."*

## **ABOUT JAGSONPAL PHARMACEUTICALS LIMITED**

Jagsonpal Pharmaceuticals Limited is a Delhi-based pharmaceutical company. Founded in 1978, the Company has a proven track record of 40+ years of catering to the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on the Gynecology and Orthopedic segments. Over the years, the Company has successfully built multiple brands that today hold market-leading position in respective segments. It has created a niche for itself in these value-accretive segments which resulted in mid-teens CAGR in revenues over the last four years reaching ₹ 2,176 Million in FY22. It has an extensive pan-India presence through its strong sales team of 900+ individuals.

Infinity Holdings acquired a majority stake in the company and is a joint promoter of the company. The company is listed on the National Stock Exchange Limited (NSE) and Bombay Stock Exchange Limited (BSE).

For more on the Company please visit. [www.jagsonpal.com](http://www.jagsonpal.com).

Mr. S.V. Subha Rao  
Chief Financial Officer  
Contact: [svrao@jagsonpal.com](mailto:svrao@jagsonpal.com); 01146181100

Jagsonpal Pharmaceuticals Limited  
CIN: L74899DL1978PLC009181  
T-210 J, Shahpur Jat, New Delhi – 110049